HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (195)	7/10/2001 5:28:19 PM
From: Icebrg	of 1022

Wilder, >>From collaboration in 1999 to entering clinical development 2001. That's cool.>> Mitch Sayare (IMGN's CEO) recently said in a webcast, that he is "calculating" with 18 months from target to IND for new TAPs. As those who follow IMGN know it is not always quite clear what timescale that is used in the company. But the announcement from ABGX seems to support his timeframe. Apart from that, the PR issued was not extremely informative. Neither the name of the MAB, its indication nor the size of the payment was mentioned. As far as Amgen is concerned. They did not even issue any PR. Perhaps it could be argued that this was a material event for Abgenix, but not for Amgen. I am confused. But that happens from time to time. I am used to it. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next